While we struggle here in the U.S. with the uncertainties of what the Sunshine Act will mean for both pharma companies and CME providers, France has been busy promulgating its own version of legislation that seeks to regulate financial transactions between pharmaceutical companies and healthcare providers. Tom Sullivan has a pretty exhaustive post on Policy and Medicine running down the details of the French Sunshine Act, as well as the current state of regulations in other European countries.
0 comments
Hide comments
